Navigation Links
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/10/2011

arch agreements

--500,000100,000Total revenues

156,352208,6521,480,362892,644Operating expenses:Research and development

6,940,5647,573,25132,797,67234,416,983Marketing

1,995,716194,8335,051,0061,049,760General and administrative

3,710,7392,074,19212,499,8778,024,138Total operating expenses

12,647,0199,842,27650,348,55543,490,881Loss from operations

(12,490,667)(9,633,624)(48,868,193)(42,598,237)Interest income and other, net

227,89955,025329,290363,998Consolidated net loss

$(12,262,768)$ (9,578,599)$(48,538,903)$(42,234,239)Net loss attributable to noncontrolling interest

316,766141,6821,199,161141,682 Net loss attributable to Optimer Pharmaceuticals, Inc. common stockholders

$(11,946,002)$ (9,436,917)$(47,339,742)$(42,092,557)Basic and diluted net loss per share attributable to common stockholders

$
(0.31)$
(0.28)$
(1.25)$
(1.30)Shares used to compute basic and diluted net  loss per share attributable to common stockholders

39,140,21433,117,09537,830,45232,468,702Optimer Pharmaceuticals, Inc.Consolidated Balance SheetsYear Ended December 31,20102009ASSETSCurrent assets:Cash and cash equivalents

$  19,861,924$ 17,054,328Short-term investments

29,553,50621,131,145Prepaid expenses and other current assets

516,859416,859Total current assets

49,932,28938,602,332Property and equipment, net

697,683672,896Long-term investments

882,000882,000Other assets

508,190498,762Total assets

$  52,020,162$ 40,655,990LIABILITIES  AND STOCKHOLDERS'  EQUITYCurrent liabilities:Accounts payable

$
2,307,820$   2,625,240Accrued expenses

2,385,0465,025,669Total current liabilities

$
4,692,866$   7,650,909Deferred rent

141,138253,474Commitments and contingencies

--Stockholders’ equity

47,186,15832,751,607Total liabilities and stockholders’ e
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... WASHINGTON , Feb. 27, 2015  Following ... Means Committee that moved H.R. 284, the Medicare ... the American Association for Homecare (AAHomecare) released a ... quick action to pass the legislation. ... in the House Ways and Means Committee is ...
(Date:2/27/2015)... 2015 Securities lawyers at Dunnam & ... Ltd. (NASDAQ: SLXP ) in connection with ... investors are encouraged to contact attorney Hamilton Lindley by ... focuses upon the shareholder value of the transaction. Under ... only $158.00 per share in cash. At least one ...
(Date:2/27/2015)... and HOUSTON, TX , Feb. 27, ... (TSX-V: EPI) and Bloom Burton & Co. Ltd. ("Bloom ... contractual lock-up (the "Lock-Up") 2,353,130 common shares of the ... originally subject to the Lock-Up. Of the Common Shares ... trading immediately upon release from the Lock-Up while the ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4
... Disease Control and Neurotoxicity Data To Be Presented ... Picoplatin as a Neuropathy-Sparing Alternative to Oxaliplatin for ... Team to Host Analyst and Investor Briefing to ... SAN FRANCISCO, Calif., May 28 Poniard Pharmaceuticals, ...
... and Melanoma Studies - Conference Call to be Hosted ... Conn., May 28 CuraGen Corporation (Nasdaq: ... data presentations from its ongoing clinical trials of CR011-vcMMAE, ... advanced breast cancer and melanoma at the 2009 Annual ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 5Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 6CuraGen to Present CR011-vcMMAE Data at ASCO 2CuraGen to Present CR011-vcMMAE Data at ASCO 3CuraGen to Present CR011-vcMMAE Data at ASCO 4CuraGen to Present CR011-vcMMAE Data at ASCO 5
(Date:3/1/2015)... 2015 A federal court overseeing ... scheduled to go to trial in October has ... to provide testimony regarding the role an Italian ... Profemur device, Bernstein Liebhard LLP comments. According to ... District of Iowa on February 25th, Wright Medical ...
(Date:3/1/2015)... 01, 2015 “ The Barrel Mill ” ... Report, which takes a look at the latest and coolest ... host of NewsWatch and a technology expert, conducted the review ... flavor to drinks. , According to Home Distillation of Alcohol, ... spirits. Well, there’s a pretty cool product that’ll help anyone ...
(Date:2/28/2015)... (PRWEB) March 01, 2015 Heart diseases ... that 10 percent of urban adult population and 5 ... of heart diseases and 20-30 percent of them require ... heart ailments and coronary vascular diseases (CVD). , A ... a new market research report titled “Indian Coronary Stent ...
(Date:2/28/2015)... Portland, Oregon (PRWEB) February 28, 2015 ... Portland, Oregon, is offering a new special. Throughout ... denture relines. , This service ... from sleep problems and pain. Patients may notice certain ... and need relining. These symptoms include: , 1.    Pain, ...
(Date:2/28/2015)... A study out of the University ... procedure for the treatment of a hereditary ocular condition ... Authored by Dr. Robert MacLaren, professor of ophthalmology at ... Medical Journal on January 16, 2014 , the study ... disorder that mostly affects men and leads to the ...
Breaking Medicine News(10 mins):Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... researchers have found that a particular resonance pattern in ... its ability to discriminate speech. ,In ... Poeppel and Huan Luo report that the inherent rhythm ... spoken sentences by changing its phase. ,The ...
... American idol winner Kelly Clarkson has revealed that she was ... interview to 'CosmoGirl!' in its August issue, the singer said ... to lose weight for a role in a play. ... thinner...then I'll get the role," Us Weekly quoted Clarkson, as ...
... wine halved in France since the 1950s, the world's number ... its saviour. But while the Chinese and Indians have ... worlds largest, there are those attending the two-yearly event who ... margins in China are not there. It is not ready ...
... a strong work ethic and sense of place appear to ... illness , in that these values may delay them from seeking ... to view their work as a lifelong endeavour, and there is ... it out or not go to the hospital, said Alex Clark, ...
... 50 years of independence this year, the fight against river ... bad news is that the parasite that causes the crippling ... one drug used to treat it. ,River blindness ... by black flies. The worms can cause intense itching, elephantiasis ...
... days is good advice for more reasons than sheer comfort. ... That's the message from the Pennsylvania Medical Society, warning young ... to be avoided at all costs - even if it ... is not an accident," says Marilyn J. Heine, M.D., an ...
Cached Medicine News:Health News:Go for Russia, Not China, Wine Experts Say 2Health News:Go for Russia, Not China, Wine Experts Say 3Health News:Rural Work Ethic Curbs Elderly Heart Care 2Health News:River Blindness Becoming Drug Resistant 2Health News:Keep a Cool Head on Hot, Humid Days to Avoid Heat Stroke 2Health News:Keep a Cool Head on Hot, Humid Days to Avoid Heat Stroke 3
... Infrapatellar Band uses an aircell ... patellar tendon helping to relieve ... patella tendonitis. Focusing the pressure ... tubercle with less constriction of ...
Both versions of the UltraSling II provide immobilization for rotator cuff repairs, capusular shifts, Bankhart repairs, glenohumeral dislocations/subluxation and soft tissue repairs/strains....
Unique V-lock strapping system prevents roll and shifting to provide secure shoulder immobilization...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: